Compare TYRA & GOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | GOOD |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 533.4M |
| IPO Year | 2021 | N/A |
| Metric | TYRA | GOOD |
|---|---|---|
| Price | $22.54 | $10.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $31.20 | $11.00 |
| AVG Volume (30 Days) | ★ 570.8K | 511.4K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 11.06% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $155,250,000.00 |
| Revenue This Year | N/A | $8.62 |
| Revenue Next Year | N/A | $6.07 |
| P/E Ratio | ★ N/A | $59.17 |
| Revenue Growth | N/A | ★ 4.95 |
| 52 Week Low | $6.42 | $10.47 |
| 52 Week High | $24.05 | $17.01 |
| Indicator | TYRA | GOOD |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 47.44 |
| Support Level | $21.66 | $10.65 |
| Resistance Level | $24.05 | $10.97 |
| Average True Range (ATR) | 1.31 | 0.19 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 67.04 | 62.47 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.